On 26 February 2019, orphan designation (EU/3/19/2138) was granted by the European Commission to Common Services Agency (National Health Services - Scotland), United Kingdom, for allogeneic anti-Epstein Barr virus cytotoxic lymphocytes expanded ex vivo for the treatment of post-transplant lymphoproliferative disorder.
Allogeneic anti-Epstein Barr virus cytotoxic T lymphocytes expanded ex vivo
|Disease / condition||
Treatment of post-transplant lymphoproliferative disorder
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: